ISPOR Marks 25th Anniversary of Flagship Journal Value in Health

Published May 2, 2023

ViH 25th Anniversary CoverLawrenceville, NJ, USA—May 2, 2022—Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR), published an editorial celebrating its 25th anniversary as the Society’s flagship HEOR journal. The article, “25 Years of Health Economics and Outcomes Research: An Exploration of Value in Health,” appears in the May 2023 issue of Value in Health.

In 1998, the inaugural Editor-in-Chief laid out a vision for Value in Health to serve as a forum where consensus can be built around development of guidelines for conducting and reporting research in the field. In their editorial, the current Editors-in-Chief, Michael F. Drummond, MCom, DPhil, University of York, York, England, UK, and C. Daniel Mullins, PhD, University of Maryland Baltimore, Baltimore, MD, USA, examine to what extent the content published in Value in Health has contributed to achieving this goal.

“We mark the 25th anniversary of the journal by examining the changes in the growth and composition of the literature and highlighting some of the key articles from the 25 top-cited items that the journal has published to date,” said Drummond and Mullins. The number of articles published has increased from 58 per year in the period from 1998-2010, to 196 per year in the period 2019-2022. In recent years, the most rapidly growing groups of papers have been those featuring methodological issues, health policy analyses, and systematic literature reviews. Another important change has been the publication of collections of papers in themed sections.

In addition, since 2011 the journal has published more than 60 ISPOR Reports. These are papers written by official ISPOR member groups and are predominantly Good Practices Reports discussing methodological issues in HEOR. Good Practices Reports have been published in all the major topic areas in the journal’s scope, and many of them are among the top 25 most cited items.

“When considering the top-cited items as a group, it does seem that a major focus of Value in Health has been on improving the conduct and reporting of HEOR studies and on developing good practice guidelines, consistent with the goal set by the founding editors of the journal,” said Drummond and Mullins. Based on its rich 25-year history, it may come as no surprise that Value in Health has emerged as one of the top-ranked journals in the HEOR field. Value in Health has been indexed in MEDLINE since 2001 when the original impact factor was 2.342. The journal’s most recent impact factor is 5.156, demonstrating the major impact Value in Health has had on the field of health economics and outcomes research.

“As the journal’s current Editors-in-Chief, we are committed to continuing to advance HEOR science and methods,” said Drummond and Mullins. “At the same time, we hope that the advancement in scientific rigor will also motivate even greater acceptance by payers, prescribers, and policy makers of those HEOR articles that apply best practices of HEOR methods to address real-world decision making by payers, prescribers, and policy makers. In turn, this will influence which evidence-based drugs and health technologies are accessed by patients and the public. As that occurs, both Value in Health and the field of HEOR will achieve the potential of improving global public health, extending life, and improving health-related quality of life.”

For more information about the 25 most cited articles in Value in Health, view the special collection here.

###

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram 

ABOUT VALUE IN HEALTH
Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2021 impact factor score is 5.156 and its 5-year impact factor score is 6.779. Value in Health is ranked 9th of 88 journals in health policy and services, 18th of 109 journals in healthcare sciences and services, and 50th of 381 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Website  | Twitter (@isporjournals)

Related Stories

ISPOR International Panel Calls for Consensus on Medication Adherence Measures

Feb 26, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced the publication of a new report from the ISPOR Medication Adherence and Persistence Special Interest Group revealing significant inconsistencies in how researchers measure the effectiveness of interventions aimed at improving medication adherence. The report, “A Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report” was published in the February 2024 issue of Value in Health.

Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program

Dec 5, 2023

Value in Health announced the publication of 2 new commentaries by leading experts in health economics and outcomes research, both of which raise important questions as the Centers for Medicare & Medicaid Services move forward to implement the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

Medicare Could Save an Additional $10 Billion Annually Across 10 Drugs by Using a Therapeutic Reference Pricing Approach in Upcoming Price Negotiations

Nov 7, 2023

Value in Health announced the publication of a study showing that United States Medicare could save up to an additional $5-$10 billion dollars annually across 10 drugs if it negotiated prices using a therapeutic reference pricing approach rather than using the statutory ceiling price alone.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×